Wyatt R, Sodroski J: The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998, 280:1884–1888. ArticlePubMedCAS Google Scholar
Richman DD, Wrin T, Little SJ, Petropoulos CJ: Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 2003, 100:4144–4149. In most HIV-infected patients, potent neutralizing antibody responses are generated early after infection, at first to the autologous-infecting HIV variant and then to subsequent variants. The data in this paper show that the antibody responses to these variants exert a selective pressure that drives continuous evolution of neutralization-escape mutants and account for the extensive variation in the env gene that is observed in the early months after primary HIV infection. ArticlePubMedCAS Google Scholar
Wei X, Decker JM, Wang S, et al.: Antibody neutralization and escape by HIV-1. Nature 2003, 422:307–312. The data in this paper show that HIV-1 readily mutates to escape the immune response. HIV-1 protects itself from the neutralizing antibodies by putting up a shield of constantly evolving sugar moieties. This glycan shield allows the virus to escape from autologous antibody and epitope-specific monoclonal antibodies. ArticlePubMedCAS Google Scholar
D’Souza MP, Livnat D, Bradac JA, Bridges SH: Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group. J Infect Dis 1997, 175:1056–1062. ArticlePubMedCAS Google Scholar
Baba TW, Liska V, Hofmann-Lehmann R, et al.: Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000, 6:200–206. ArticlePubMedCAS Google Scholar
Mascola JR, Lewis MG, Stiegler G, et al.: Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999, 73:4009–4018. PubMedCAS Google Scholar
Parren PW, Marx PA, Hessell AJ, et al.: Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001, 75:8340–8347. ArticlePubMedCAS Google Scholar
Klasse PJ, Sattentau QJ: Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J Gen Virol 2002, 83:2091–2108. PubMedCAS Google Scholar
Earl PL, Sugiura W, Montefiori DC, et al.: Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol 2001, 75:645–653. ArticlePubMedCAS Google Scholar
Srivastava IK, VanDorsten K, Vojtech L, et al.: Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J Virol 2003, 77:2310–2320. ArticlePubMedCAS Google Scholar
Barnett SW, Lu S, Srivastava I, et al.: The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 2001, 75:5526–5540. ArticlePubMedCAS Google Scholar
Hoffman TL, LaBranche CC, Zhang W, et al.: Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. Proc Natl Acad Sci U S A 1999, 96:6359–6364. ArticlePubMedCAS Google Scholar
Weaver EA, Lu Z, Li Y, Liao HX: Immunogenicity of HIV-1 group M consensus env immunogens. Paper presented at the AIDS Vaccine Conference. New York, NY; September 18, 2003.
Slobod KS, Lockey TD, Howlett N, et al.: Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1. Eur J Clin Microbiol Infect Dis 2004, in press.
Montefiori D: Multicenter collaborative study comparing PBMC to genetically engineered cell lines for measuring neutralizing antibodies with candidate HIV-1 vaccine strains. Paper presented at the Keystone Symposium on HIV Vaccine Development: Immunological and Biological Challenges. Banff, Alberta, Canada; March 29, 2003.
Follmann D, Gilbert P, Self S, et al.: An independent analysis of the effect of race in VAX004. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8–11, 2004.
Montefiori D, Metch B, McElrath MJ, et al.: Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120. Submitted for publication.
Ogg GS, Jin X, Bonhoeffer S, et al.: Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998, 279:2103–2106. ArticlePubMedCAS Google Scholar
Pantaleo G, Demarest JF, Soudeyns H, et al.: Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. Nature 1994, 370:463–467. ArticlePubMedCAS Google Scholar
Zhu T, Corey L, Hwangbo Y, et al.: Persistence of extraordinarily low levels of genetically homogeneous human immunodeficiency virus type 1 in exposed seronegative individuals. J Virol 2003, 77:6108–6116. Some exposed but seemingly uninfected individuals show evidence of low-level HIV infection. These individuals do not show clinical signs of HIV infection, are seronegative, exhibit HIV-specific cytotoxicity, and do not have detectable levels of HIV in their blood or lymphoid tissues. The virus was found to be genetically homogeneous, suggesting that it is not replicating. These findings suggest that some individuals can control HIV infection, although the reason for the control is unknown. ArticlePubMedCAS Google Scholar
Migueles SA, Laborico AC, Shupert WL, et al.: HIV-specific CD8+ T-cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002, 3:1061–1068. ArticlePubMedCAS Google Scholar
Kaslow RA, Carrington M, Apple R, et al.: Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996, 2:405–411. ArticlePubMedCAS Google Scholar
Kaslow RA, Rivers C, Tang J, et al.: Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines. J Virol 2001, 75:8681–8689. ArticlePubMedCAS Google Scholar
Carrington M, Nelson GW, Martin MP, et al.: HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 1999, 283:1748–1752. ArticlePubMedCAS Google Scholar
Moore CB, John M, James IR, et al.: Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002, 296:1439–1443. ArticlePubMedCAS Google Scholar
Barouch DH, Kunstman J, Kuroda MJ, et al.: Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002, 415:335–339. ArticlePubMedCAS Google Scholar
Goulder PJ, Brander C, Tang Y, et al.: Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 2001, 412:334–338. ArticlePubMedCAS Google Scholar
Leslie AJ, Pfafferott KJ, Chetty P, et al.: HIV evolution: CTL escape mutation and reversion following transmission. Nat Med 2004, 3:282–289. ArticleCAS Google Scholar
Douek DC, Brenchley JM, Betts MR, et al.: HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002, 417:95–98. ArticlePubMedCAS Google Scholar
Sun JC, Bevan MJ: Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 2003, 300:339–342. ArticlePubMedCAS Google Scholar
Shedlock DJ, Shen H: Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003, 300:337–339. ArticlePubMedCAS Google Scholar
Rosenberg ES, Billingsley JM, Caliendo AM, et al.: Vigorous HIV-1-specific CD4+ T-cell responses associated with control of viremia. Science 1997, 278:1447–1450. ArticlePubMedCAS Google Scholar
Nabel GJ: Challenges and opportunities for development of an AIDS vaccine. Nature 2001, 410:1002–1007. ArticlePubMedCAS Google Scholar
Barouch DH, Santra S, Schmitz JE, et al.: Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000, 290:486–492. ArticlePubMedCAS Google Scholar
Boyer JD, Kutzler M, Robinson T, et al.: Improved cellular immune potency by Th1 cytokine-adjuvanted DNA vaccines in non-human primates. Paper presented at the AIDS Vaccine Conference. New York, NY; September 18, 2003.
McMichael A, Mwau M, Hanke T: Design and tests of an HIV vaccine. Br Med Bull 2002, 62:87–98. ArticlePubMed Google Scholar
Wilson CC, Palmer B, Southwood S, et al.: Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper t-lymphocyte epitopes. J Virol 2001, 75:4195–4207. ArticlePubMedCAS Google Scholar
Seth A, Ourmanov I, Schmitz JE, et al.: Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J Virol 2000, 74:2502–2509. ArticlePubMedCAS Google Scholar
Shiver JW, Fu TM, Chen L, et al.: Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002, 415:331–335. ArticlePubMedCAS Google Scholar
Buge SL, Murty L, Arora K, et al.: Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251. J Virol 1999, 73:7430–7440. PubMedCAS Google Scholar
Amara RR, Villinger F, Altman JD, et al.: Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/ MVA vaccine. Science 2001, 292:69–74. ArticlePubMedCAS Google Scholar
Horton H, Vogel TU, Carter DK, et al.: Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J Virol 2002, 76:7187–7202. ArticlePubMedCAS Google Scholar
Casimiro D, Bett A, Fu TM, et al.: Evaluation of heterologous prime-boost strategies involving adenovirus and poxvirus vectors for HIV vaccination. Paper presented at the Keystone Symposium on HIV Vaccine Development: Immunological and Biological Challenges. Banff, Alberta, Canada; March 29, 2003.
Burton DR, Desrosiers RC, Doms RW, et al.: Public health: a sound rationale needed for phase III HIV-1 vaccine trials. Science 2004, 303:316. ArticlePubMedCAS Google Scholar
Neil JG, Johnston MI, Birx DL, Tramont EC: HIV vaccine trial justified. Science 2004, 303:961. Article Google Scholar